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INTRODUCTION 
Across the world, Carcinoma of the Prostate is one of the most 
common malignancies, the accurate diagnosis of which is of major 
concern. In the list of malignancies excluding skin cancers, it comes 
second.
36 
Its incidence has steadily risen with time. This is attributed to the 
increased life span and also to the westernisation of lifestyle typified by 
diet with high calories and inadequate exercise to the body
14
. 
Serum PSA is increasingly being used as a screening tool. 
Consequent to it, prostate needle biopsies are increasingly performed in 
men.  Increased prostate-specific antigen levels increases needle biopsies, 
for the exclusion of prostate cancer.   
Prostatic needle biopsy is the preferred method. It has fewer side 
effects, and helps with accurate information regarding degree of tumor 
extension. The grade of tumor is also diagnosed with precision.   
But, a needle biopsy presents problems. Only a small tissue amount 
is provided for microscopic examination. It is a difficult task to accurately 
diagnose small foci of prostate cancer for pathologists and to distinguish 
cancer from  its benign mimickers. Small malignant infiltrating glands 
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graded as 6 on the Gleason score pose the volume of difficulty in 
prostatic specimens
30
. 
Only a few glands may be malignant, and they can be easily 
overlooked.  To diagnose prostate cancer, no specific single histologic 
feature is sufficiently available. The combination of architectural and 
cytologic change gives the diagnostic clue.
30 
There are numerous benign mimickers posing as prostate cancer. 
These include benign conditions including atrophy, basal cell hyperplasia, 
small crowded glands and inflammatory atypia.
30 
Wrong diagnosis leads to serious issues, like radiation induced 
adverse effects, prostatectomies done unnecessarily because of falsely 
positive diagnosis. Also, falsely negative results cause delay in early 
effective treatment. Hence, definitive diagnosis with the available 
specimen is essential for the benefit of patients.
30 
Basal cells are noted in Benign glands. Prostate cancers do not 
contain basal cells. This helps in the diagnosis of specimens. Here comes 
the vital role of Immunohistochemistry. This is used by pathologists to 
diagnose suspicious lesions in small foci accurately. 34βE12 is a marker 
which is a high-molecular-weight cytokeratin, which takes positivity in  
benign glands. p63 is a newer basal cell marker.  
17 
 
The diagnosis of prostate adenocarcinoma is supported by the basal 
cells‟ absence.  However high-molecular-weight cytokeratin and p63 are 
negative markers for prostatic carcinoma. 
AMACR (α-Methyl Acyl CoA Racemase) is used in the diagnosis 
of prostate cancers as a positive marker with high sensitivity (76 – 100%) 
and high specificity(75 – 95%)36 
  So, the aim of this study is to study expression and use of 
immunohistochemical markers in various prostate biopsies. The role of 
HMWCK (34βE12) and AMACR (P504S) in diagnosis of prostate 
specimens is studied 
  
18 
 
 AIM OF THE STUDY 
     To study the Expression and Diagnostic utility of 
Immunohistochemical markers AMACR and 34βE12 in various Prostatic 
lesions. 
OBJECTIVES OF THE STUDY 
1. To find out the incidence of various prostatic lesions in men 
2. To study the clinical presentation of prostatic lesions 
3. To study the sensitivity and specificity of AMACR and 34βE12 
4. To study the expression of AMACR and 34βE12 in various prostatic 
lesions 
5. To study the use of AMACR and 34βE12 in detecting limited 
samples of prostate . 
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REVIEW OF LITERATURE 
Cancers of the Prostate account for the highest incidence of 
malignancies in men and is the second most common cause of morbidity. 
PSA used as a screening tool has resulted in Needle biopsies of the 
Prostate increasingly being performed. It has also increased the cases of 
difficult biopsies. 
ANATOMY OF PROSTATE 
Prostate is a functional coundit which allows urine to pass from 
urinary bladder to the urethra. It adds nutritional secretions to the sperm 
to form semen during ejaculation.
57 
Prostate is a tubulo alveolar gland located in true pelvis. Normal 
prostate in adults measures 4 x 3 x 2cms. Anatomically it is divided into 
glandular and nonglandular components. 
Glandular components include Peripheral zone, Central zone, 
Transition zone and Periurethral gland zone. 
  Non glandular components include Anterior fibromuscular 
stroma, preprostatic sphincter, striated sphincter. 
The normal adult prostate weighs approximately 30g and is funnel 
shaped. The prostate gland consists of concentric inner zone and outer 
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zone. Clinically detectable carcinomas affect the outer zone and BPH 
affects the inner aspect of the gland.
57
  
It receives arterial supply from inferior vesical and middle rectal 
arteries, branches of internal iliac arteries. Prostatic venous plexus drains 
into internal iliac vein. Primary lymphatics drain into regional 
lymphnodes. 
HISTOLOGY 
The epithelial cells of prostate are Transitional, Secretory, Basal 
cell, and Neuroendocrine cell. 
TYPES OF SPECIMEN 
Needle biopsies
58 
TRUS guided core biopsies (Trans Rectal UltraSound guided) for 
diagnosis of prostate cancer is the Gold standard method now.  
The standard protocol says that lesions identified on ultrasound or 
digital rectal examination have to be correlated with systematic biopsies. 
The bilateral apex, mid and base regions are included in the sextant 
protocol. 
 The center of each prostate‟s  half is aimed at in Sextant biopsies. 
It is ensured that it is of equal distance, both from the lateral edge and the 
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midline. The dorsolateral region is the most common site of prostate 
cancer.  
Many modifications of the said biopsy protocol have been 
suggested. Studies conducted recently say that protocols containing ten to 
thirteen systematic biopsies are superior with detection of prostatic 
cancers in about 35% of cases. This is better than the existent sextant 
protocol done traditionally.  
Handling of needle biopsies
58
. 
The identification of the different glandular areas in biopsies of the 
Prostate is essential. The location of the biopsy site is to be known 
because, between base and apex, there is difference in the standard 
histology. 
The clinician considers the extent and location when selecting 
options of treatment. 
Trans Urethral Resection of Prostate(TURP)
58 
 TURP detected Cancers are frequently transition zone tumours. 
when large, they may originate from the peripheral zone. More than 100g 
tissue may be present in a TURP sample. It is frequently necessary, for 
histological examination, to select a limited tissue amount. 
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Pathologic features 
 Gross examination  of TURP specimens is of little significance, 
because benign processes can mimic prostate carcinoma. 
Radical prostatectomies 
          Grossly identifiable prostate carcinoma is typically of higher grade 
and stage and larger diameter. In contrast to the adjacent normal prostate 
tissue, which appears tan and spongy, grossly evident prostate carcinoma 
is solid and firm. It ranges between white grey and yellow orange in 
color. 
         Prostate carcinomas discovered by PSA screening are less visible 
grossly, these cancers are often small(<5mm) and of lower grade and 
stage. 
Patterns of spread and metastasis
58,59
: 
Local extraprostatic extension typically occurs anteriorly for 
transition zone cancer ,posteriorly and posterolaterally for peripheral zone 
cancer. Prostate carcinoma can also spread superiorly into the bladder 
neck. Rarely, it can penetrate Deninvillier‟s fascia posteriorly to involve 
the rectum. Metastatic prostate carcinoma most commonly causes node 
enlargement regionally and affects axial skeleton bones and pelvis.  
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Gleason Grading System  
Gleason grading system, designed by Dr. Donald Gleason, is the 
predominant grading system for prostate carcinoma. Architecture of the 
glands forms the basis; evaluation of nuclear atypia is not done. With 
decreasing glandular differentiation, 5 histologic patterns are defined. 
To get the Gleason score the first and second common patterns (in order 
of prevalence) are added. If a prostate carcinoma only has one pattern, 
doubling of the pattern is done to get the Gleason score. Along with the 
Gleason score, reporting of primary and secondary patterns is to be 
done.  
Recently, several modifications have been made to the original 
Gleason grading scheme in an effort to adapt this grading system to 
present-day practice in a similar way. The modified Gleason grading 
system is given below. The significant changes include a stricter 
definition of Gleason pattern 3 cribriform glands, and grading ill-
defined glands with poorly formed glandular lumina as pattern 4. 
Gleason’s microscopic grading system of prostatic carcinoma60 
Grade 1 Separate, single , uniform glands in closely packed masses 
with                                                                                                           
usually rounded, definite, edge limiting the areas of tumor 
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Grade 2 Nodular, separate, single, slightly less uniform glands, with 
less sharp edge(loosely packed) 
Grade 3a Separate, single, much more variable glands, usually 
irregularly separated, may be closely packed but poorly 
defined, ragged edge 
Grade 3b Like 3a, but tiny cell clusters or very small glands  
Grade 3c Smoothly and sharply circumscribed masses of loose 
cribriform or papillary tumor. 
Grade 4a Raggedly infiltrating, raggedly outlined glandular tumor in a 
fused manner. 
Grade 4b Like 4a,with pale large (hypernephroid) cells  
Grade 5a Rounded, sharply circumscribed masses usually with central 
necrosis; of almost solid cribriform tumor. 
Grade 5b  Ragged masses of anaplastic carcinoma with only vacuoles or 
enough gland formation for identification as adenocarcinoma 
Gleason Pattern 1.
58 
        This pattern is composed of a well-circumscribed nodule of tightly 
packed, uniform but separate glands. There is no or minimal infiltration 
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into adjacent tissue. The glands are similar in size or of intermediate 
size and shape. It is a very rare pattern. It is usually present in transition 
zone of cancers of prostate. The Gleason grading system with new 
modifications states that Gleason score of 2(1 + 1) is a grade that should 
be reported very rarely. It is commonly, only a minor component of 
carcinoma specimen. 
Gleason Pattern 2. 
       There is a less well-circumscribed nodule of medium-sized glands, 
with some degree of variation in size and shape and looser arrangement. 
Gleason pattern 2 carcinoma is commonly seen in the transition zone. 
There can be minimal invasion of carcinomatous glands into adjacent 
tissue. Cytoplasm, in the grading by Gleason system, is not evaluated. 
But in Gleason patterns 1 and 2, the glands are pale-clear and abundant.  
Gleason Pattern 3 
         This is the pattern with the highest frequency. The carcinomatous 
glands commonly infiltrate between the surrounding benign glands. 
They are commonly angular and vary in shape and size. Typical patterns 
are seen with small glands. When they are large, they have a cribriform 
or papillary configuration. The Gleason pattern 3 cribriform glands have 
smooth, round contours, in contrast to the large, irregular, pattern 4 of 
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Gleason, cribriform glands. 
Gleason Pattern 4 
In this pattern, the glands are poorly formed, cribriform or fused. 
Fused glands comprise a group of glands which are not separated by any 
stroma. Cribriform glands in pattern 4 are large and have irregular 
contour and jagged edges. The intraluminal cellular proliferation spans 
the entire diameter of the lumen. Poorly formed glands still have 
glandular configuration, but they have ill-formed glandular lumina. The 
hypernephromatoid pattern is an uncommon variant composed of fused 
glands showing very pale or clear cytoplasm. 
Gleason Pattern 5 
         Cancer cells lack glandular differentiation. They manifest as 
strands, solid sheets, or single cells infiltrating the stroma. Comedo 
necrosis may be seen. 
Tertiary pattern 
       Tertiary Gleason pattern refers to a minor pattern occupying less 
than 5% of the tumor volume. In radical prostatectomy, when high-
grade tertiary pattern is seen, it affects the prognosis worsely. A bad 
prognosis is seen in a tertiary pattern five (Gleason score 4 + 3 = 7) 
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prostate carcinoma. In comparison, where a tertiary high-grade 
component is not seen, the same lesion has a relatively better prognosis. 
But, the prognosis isn‟t as bad as that of a 4 + 5 = 9 carcinoma. In 
prostate needle biopsies that harbor three patterns when the worst 
pattern is the least common, the highest pattern should be incorporated 
as the secondary pattern. 
Grading of morphological variants 
Morphologic variants of prostate carcinoma are uncommon and 
often are mixed with ordinary prostate carcinoma. Grading such variants 
should be based on the underlying cancer glandular architecture. In 
general, ductal adenocarcinoma and mucinous adenocarcinoma behave 
more aggressively, comparable to Gleason score 8 acinar cancers. 
Signet-ring cell and sarcomatoid variants are even more aggressive, 
comparable to Gleason score 9 or 10. On the other hand, squamous cell 
cancers, cancers of the urothelium, small cell cancers, and 
basaloid/adenoid cystic carcinoma are not assigned a Gleason grade. 
Prostate carcinoma treated with hormonal ablation or radiation 
can appear artefactually to of higher Gleason grade.Therefore, Gleason 
grade should not be assigned to such cases. If no effect of the therapy is 
evident, a Gleason grade can be assigned. 
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Prostate carcinoma displays a remarkable intratumoral grade 
heterogeneity; therefore, the biopsy Gleason grade may in some cases 
represent undergrading or overgrading compared with the radical 
prostatectomy. Nevertheless, the concordance between needle biopsy 
and prostatectomy Gleason scores is mostly within 1 Gleason score. 
Multiple studies have demonstrated that the Gleason grade is 
currently a very powerful prognostic indicator for cancers of the 
prostate. In radical prostatectomies, there is a good correlation with all 
the significant pathologic criteria, and with prognosis secondary to 
radical prostatectomy or radiation therapy. The distinction between 
Gleason scores 6 and 7 is difficult as well as important.Gleason 7 
prostate carcinoma behaves significantly worse than Gleason 6 cancer 
but better than Gleason score 8 to 10 cancer.  
Prognosis 
The following Gleason scores combinations fall into similar 
prognosis groups: 
Gleason score 2 to 4    - well-differentiated 
 Gleason score 5 to 6   - moderately differentiated 
 Gleason score 7         - moderately to poorly differentiated 
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Gleason score 8 to 10   - poorly differentiated. 
The use of many names to predict progression of disease (after 
radiotherapy and surgery) and pathologic stage stress the significance of 
Gleason grade. These nomograms, including Partin tables and Kattan 
nomograms, use preoperative biopsy Gleason score, tumor extent, 
clinical stage, and serum PSA to predict the risk of invasion of seminal 
vesicle, adjacent extension, and nodal metastasis and probability of 
disease recurrence after treatment. 
 Prostate cancer diagnosis is usually made using histological, 
traditional parameters, not with any single diagnostic feature. They 
include nuclear features, tissue architecture and other features. In needle 
biopsies, tissue diagnosis of prostatic carcinoma is difficult. This is 
because of either the many benign mimickers of malignancy or a small 
focus of cancer. 
Microscopic Findings 
Prostate cancer has a collection of architectural, cytoplasmic, 
nuclear features
36
. 
Prostate Carcinoma – Pathologic Features 
Gross Findings 
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 Firm, solid, white grey to yellow orange in contrast to tan, 
Spongy benign prostatic tissue 
 PSA-detected cancer often not grossly visible 
MICROSCOPIC FINDINGS OF PROSTATIC CARCINOMA 
 Architecture features: 
       Haphazard glandular arrangement; infiltrative growth; less 
differentiated glands with cribriform, fused glands, cords, sheets, 
or single tumor cell. Typically small glands with straight luminal 
border 
 Cytologic features: 
Pale to amphophilic cytoplasm; no lipofuscin pigment 
 Nuclear features: 
Enlargement, hyperchromasia, variably prominent nucleoli. 
 Cancer-specific features: 
Mucinous fibroplasias (collagenous mironodules); 
glomeruloid formation; perineural invasion.  
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Histologic Variants of Prostate Carcinoma 
 Ductal adenocarcinoma 
 Atrophic carcinoma 
 Pseudohyperplastic carcinoma 
 Foamy gland carcinoma 
 Mucinous carcinoma 
 Small cell carcinoma 
 Signet-ring carcinoma 
 Squamous cell cancer 
 Sarcomatoid carcinoma 
 Urothelial carcinoma 
 Basaloid carcinoma 
Differential Diagnosis 
 Normal prostatic/nonprostatic tissue (verumontanum glands, 
Cowper‟s glands, paraganglia, seminal vesicle/ejaculatory duct, 
mesonephric remnants) 
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 Benign conditions (atrophy, partial atrophy, postatrophic 
hyperplasia, urothelial/squamous metaplasia, basal cell 
hyperplasia, adenosis, sclerosing adenosis, inflammation, 
nonspecific granulomatous prostatitis, BPH) 
 HGPIN 
 Treatment effect (radiation atypia) 
 The differential diagnosis of prostate carcinoma is complex. In 
many instances, the differential is with normal prostatic and 
nonprostatic structures, including seminal vesicles/ejaculatory duct 
epithelium, Cowper‟s gland, paraganglia, and mesonephric duct 
remnants. A wide variety of benign pathologic processes, such as 
inflammation, atrophy (simple atrophy, partial atrophy, and 
postatrophic hyperplasia), metaplasia (urothelial, squamous, and 
mucinous), basal cell hyperplasia, BPH, and radiation and hormonal 
treatment effects, can simulate prostate carcinoma to varying degrees. 
The prostate gland can rarely be involved by primary urothelial, small 
cell, mucinous, and signet-ring cell carcinoma. However, such a 
diagnosis should be made only after a metastasis from other sites is 
diligently excluded.  
 On the other hand, prostate carcinoma can also mimic benign 
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conditions. For example, a well-differentiated Gleason score 2 to 4 
prostate carcinoma should always be differentiated from adenosis. 
Cribriform prostate carcinoma should be distinguished from benign 
cribriform hyperplasia or cribriform HGPIN. Atrophic and foamy 
prostatic carcinomas may be confused with benign atrophy and 
Xanthoma, respectively. Pseudohyperplastic prostate carcinoma 
shares some architectural features with BPH, although the former 
invariably has significant nuclear atypia. Careful evaluation of the 
architectural and cytologic features and prudent use of AMACR and 
basal cell markers will lead to a correct diagnosis. 
 Atypical small acinar proliferation (ASAP)1,35 
 Sometimes a glandular focus or gland raises suspicion of 
prostate carcinoma, yet a definitive cancer diagnosis cannot be 
established due to the lack of sufficient architectural and cytologic 
atypia. The terms “atypical small acinar proliferation (ASAP)” and 
“focal atypical glands” have been used. Unlike HGPIN or prostate 
carcinoma, ASAP is a diagnostic term rather than a defined disease 
entity. It encompasses such lesions as HGPIN, reactive atypia, benign 
mimickers of prostate carcinoma and cases of focal cancer. ASAP 
found in needle biopsy denotes a high risk ( ᷉  50%) of detecting 
prostate carcinoma in subsequent biopsies. 
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The following are the benign mimickers of prostate, 
BENIGN MIMICKERS OF PROSTATE 
2,9,36 
 
1. Adenosis,  
2. Atrophy, 
3. Partial atrophy,  
4. Clear cell hyperplasia, 
5. Basal cell hyperplasia,  
6. Post atrophic hyperplasia,  
7. Mesonephric hyperplasia,  
8. Nephrogenic adenoma, 
9. Seminal vesicle & Cowpers glands.  
The following are the features help to differentiate prostate cancer from 
its benign mimickers. 
Architecture 
      Gland-forming prostate carcinomas are more crowded than benign 
glands and typically exhibit a haphazard growth pattern, with malignant 
glands separated irregularly by bundles of smooth muscle and 
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perpendicular orientation to each other. They also display "infiltrative 
growth pattern," with malignant glands situated between or flanking 
benign glands. When prostate carcinoma becomes less differentiated, it 
loses glandular differentiation and forms cribriform structures, fused 
glands, poorly delineated glands, solid sheets or cords, or even single 
tumor cells. 
Cytoplasm.  
       In contrast to benign glands with irregular and undulating luminal 
borders, prostate carcinoma glands are smaller and have straight luminal 
borders. They may have arnphophilic, or darker, cytoplasm that is 
evident even at low magnification. However, low-grade prostate 
carcinoma often has pale-clear cytoplasm, indistinct from benign glands. 
Prostate carcinoma typically lacks lipofuscin pigment. 
Nuclei 
     Typically, prostate cancer shows nuclear features which is distinct 
from its surrounding benign glands. Some prostate cancers have 
hyperchromatic and enlarged nuclei and do not show prominent 
nucleoli. Apoptotic bodies and Mitoses are more frequent in prostate 
cancer, but they are infrequent in benign glands.. 
Intraluminal content. 
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Crystalloids - dense eosinophilic, crystal-like structures found 
within the glandular lumina - are found more commonly in carcinoma. 
However, they are also frequently found in adenosis, a benign condition 
that mimics low- grade prostate carcinoma. Intraluminal pink, acellular, 
dense secretions mucin  are additional findings seen preferentially in 
prostate carcinoma. In contrast, corpora arnylacea are commoner in 
glands of benign nature and are not commonly seen in prostate cancer. 
Stroma. 
      Ordinary prostate carcinoma does not elicit a desmoplastic response 
or stromal inflammatory reaction. Ductal adenocarcinoma of prostatic 
origin, however, may induce such stromal reactions with fibrosis 
containing hemosiderin- laden macrophages. 
Cancer-specific features. 
There are 3 histologic features diagnostic of prostate cancer, 
because they are not seen in benign glands. Mucinous fibroplasia, or 
collagenous micronodules are seen within or adjacent to cancer glands. 
It  is frequently surrounded by a crescentic space, resembling 
glomerulus of kidney . The pathognomonic feature of prostate cancer is 
Perineural invasion with completely or near-completely encircling the 
cancer glands. The circumferential expansion of benign glands about a 
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nerve has not been mentioned. 
Prostatic biopsies sometimes show small foci of proliferative 
atypical acini. They show some features diagnostic of adenocarcinoma, 
but not all. A variety of terms like suspicious, suspicious -  but not 
diagnostic of malignancy, atypical focus and atypical small acinar 
proliferation (ASAP) have been used to describe them. ASAP is the most 
accepted term of these
36
. 
ASAP include lesions such as BCH, atrophy, HGPIN, atypical 
adenomatous hyperplasia, reactive atypia. The list also includes cases 
which in retrospect display minute carcinoma but contain inadequate 
architectural or cytological atypia for concrete diagnosis of carcinoma. 
The chance of occurence of prostate carcinoma on subsequent biopsy in 
people with ASAP diagnosis on initial biopsy varies between 21% and 
49%
36
. 
Among the prostate cancer -  benign mimickers, partial atrophy and 
atrophy are often wrongly diagnosed as prostate cancer.
37,45
 Maintenance 
of lobular architecture , absence of nucleoli, uniformity of cytology, and 
presence of a layer of basal cells are some of the criteria against the 
diagnosis of cancer.  
  
38 
 
Prostatic partial atrophy: 
             It is the commonest benign mimicker of prostatic carcinoma. It 
has a diffuse growth pattern with features of glandular crowding and is 
frequently lobular to disorganized. Glands often have undulating luminal 
surfaces with papillary infoldings. Cytoplasm is pale-staining. Nuclei are 
more spaced than in typical atrophy. In areas, nuclei reach the full height 
of the cells and are usually benign-appearing. On occasion, prominent 
nucleoli may be present, although they are typically not as large as seen 
in prostatic adenocarcinoma. It is often difficult to identify basal cells in 
partial atrophy on H&E-stained sections. Therefore, it is commonly 
confused with prostatic adenocarcinoma. 
Partial atrophy
36
:  
The pattern is lobular to disorganized with glandular crowding . 
The cells are paler and angulated. Nuclei are sometimes large with  
prominent nucleoli. Pseudo nerve invasion and absent/ patchy basal cells 
make it to mimic adenocarcinoma. 
Adenosis  
This contain severely crowded small glands, with more benign 
glands admixed with them. Glands show pale to clear cytoplasm. The 
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nuclei do not have a very prominent nucleoli. There is a continuous or 
fragmented basal cell layer. 
Basal cell hyperplasia :       
 This mimicks prostate adenocarcinoma commonly in needle 
biopsies. It is commonly visualised in the transition zone. It shows 
nodular expansion of round uniform glands seen with a clear cytoplasm. 
Seen are basal cells in multiple layers. With scant cytoplasm, they are 
dark; and show oval or round hyperchromatic spindled nuclei. They are 
usually negative for racemase and with basal cell markers, stain 
positively
36
. 
Nephrogenic adenoma: 
53 
It can uncommonly affect the prostatic urethra and is a metaplastic, 
benign response to injury by the urothelium. Extension into the 
underlying fibromuscular prostatic stroma by small tubules of 
nephrogenic adenoma can cause a wrong diagnosis of prostate cancer of 
low grade. 
Cowpers glands: 
It can look similar to either foamy gland carcinoma or low grade 
adenocarcinoma. A bland cytological picture is seen in either.  
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Seminal vesicle : 
 Sometimes, seminal vesicles seen on biopsy specimens can mimic 
prostate cancer. It is seen with the seminal vesicle‟s complex papillary 
architecture visualised at the tissue core‟s edge with surrounding small 
glandular clusters. A leading point is lipofusin granules in abundance in 
the seminal vesicle‟s cytoplasm. 
PIN: Prostatic Intraepithelial Neoplasia
32
:       
              PIN is the abnormal proliferation of foci of premalignancy, with 
carcinoma in situ and cellular dysplasia; there is no stromal invasion 
within the ductules, large acini and prostatic ducts. 
           The prostate‟s peripheral zone is the region where most of prostate 
cancers occur. It is also the commonest site for PIN.  PIN is seen 
commonly in the peripheral zone, displaying multicentricity. 
The commonest preinvasive stage of prostate cancer is Prostatic 
Intraepithelial Neoplasia. PIN has a significantly high predictive value as 
an indicator for prostate cancer. The diagnosis needs a repeat biopsy to 
rule out subsequent or concurrent invasive cancer. 
There is no significant elevation of serum PSA - prostate-specific 
antigen in PIN. Neither is there any in their derivatives. Present imaging 
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methods such as ultrasound cannot detect PIN. Biopsy is the only 
available detection method. Many PIN patients, within 10 years, will go 
on to develop cancer. Androgen deprivation therapy has, in 
chemoprevention, a significant role. It reduces the extent and prevalence 
of PIN. 
Grading
26,56
:          
Previously graded from 1 to 3, Prostatic intraepithelial neoplasia 
currently recommends 2 grades of PIN (low & high grade). Low-grade 
PIN was Grade 1, high-grade PIN included grades 2 and 3. Presently, 
without qualification, „PIN‟ means only high-grade PIN. The important 
distinguishing feature between high and low grade PIN is, rather than 
architecture, the nuclear appearance.  
The earliest accepted stage in carcinogenesis is High-grade 
prostatic intraepithelial neoplasia (PIN). It has most of the biochemical, 
phenotypic and genetic changes of cancer. PIN doesn‟t invade the acini‟s 
basement membrane. 
4 main patterns in high-grade PIN exist:  
   1. Tufting 
   2. Cribiform 
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   3. Flat /Atrophic. 
   4. Micropapillary 
          Among this, tufting pattern is the most common pattern
36
, it 
presents in about 97% of cases. According to a report, a higher coexistent 
cancer risk is noted with the cribriform pattern. High-grade PIN has no 
clinically known significant differences between architectural patterns.  
Other unusual patterns: 
These include Foamy gland pattern, small-cell neuroendocrine 
pattern and signet ring cell pattern.  
The earliest evidence of cancer is early invasion of stroma. It 
occurs with high-grade PIN at sites of basal cell disruption and acinar 
outpouching in acini. Nearly 2% PIN show such microinvasion and is 
seen with equal frequency in all architectural patterns.  
PIN Differential diagnosis 
PIN‟s differential diagnosis includes 
1. Lobular atrophy 
2. Post atrophic hyperplasia 
3. Atypical basal cell hyperplasia 
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4. Cribriform hyperplasia 
5. Metaplastic changes 
           The most common benign lesions mimicking HGPIN are basal cell 
hyperplasia and cribriform hyperplasia. 
PIN was often diagnosed as adenocarcinoma as showed in a study 
from the Mayo Clinic files of transurethral resections from 1960 to 1970. 
Likewise, clusters of PIN are wrongly diagnosed as cancer in 
prostate fine-needle aspiration. 
In diagnostic pathology, the detection of limited prostate cancer is 
a difficult challenge. Differences between atypical glands and benign 
glands in cytoplasmic features, nuclear features and intraluminal contents 
are to be known. This assists in diagnosing on needle biopsy, small foci 
of atypical glands.. 
In the diagnosis of limited adenocarcinoma, Immunohistochemistry 
in prostate needle biopsies plays a vital role. High molecular weight 
cytokeratin and p63 are basal cell markers which stain positively in basal 
cells. They are not seen in carcinoma of the prostate. But there are 
problems in specificity and sensitivity in immunohistochemistry studies. 
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Features favouring the diagnosis of limited prostate 
adenocarcinoma
28,43 
Diagnostic of cancer 
Mucinous fibroplasia 
Glomerulations 
Perineural invasion 
Favoring cancer 
Nuclear Hyperchromasia 
Prominent nucleoli 
Nuclear Enlargement 
Cytoplasmic Amphophilia 
Straight, even luminal borders 
Mitotic figures 
Basophilic mucinous secretions 
Intraluminal Pink dense secretions 
Crystalloids 
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Features against the diagnosis of limited adenocarcinoma 
Inflammation 
Adjacent PIN 
Small glands merging with benign glands 
Tangential section or outpouching of PIN 
Atrophic features  
CARCINOMAS MIMICKING BENIGN GLANDS
22,32 
Between 5% and 10% of prostate cancers are histologic 
variants. They are consistently seen related with acinar prostate 
cancer. The histological variants, several times differ from cancer in 
clinical, immunophenotypic, ultra structural and genetic features. 
They also differ in their therapeutic approach and prognosis. 
Some carcinomas resemble benign prostate glands in their 
architectural pattern similar to benign mimickers of prostate cancer. They 
may not be recognized as carcinomas.They are : 
1. Foamy gland cancers 
2. Peudohyperplastic prostatic cancers 
3. Atropic prostatic cancers                 
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1.Foamy gland cancer 
Cancer cells have abundant foamy or "xanthoma"-like 
cytoplasm. Even though the cytoplasm has a xanthomatous 
appearance, it contains empty vacuoles rather than lipid. There is a 
very low nuclear/cytoplasmic ratio. In foamy gland prostate cancer 
cells nuclei are typically hyperchromatic and small.. The diagnosis of 
foamy gland prostate carcinoma is based on its architectural pattern of 
infiltrative and/or crowded glands, abundant foamy cytoplasm, and 
frequent pink, dense, acellular intraluminal secretions. Even with its 
bland cytology, most of the cases have Gleason score 6 or greater. It 
is consequently, reported as a intermediate-grade carcinoma. 
The diagnosis is aided by its architectural pattern of infiltrative 
glands, foamy, abundant cytoplasm, and frequently present acellular pink 
secretion. Prominent nucleoli and nuclear enlargement, which are the 
common features of adenocarcinoma, are often not seen. This makes this 
lesion difficult to diagnose as carcinoma. 
Nuclei occupy only 10% of the cell height in foamy gland 
carcinoma because of the copious cytoplasm. Typically, the nuclei in 
foamy gland carcinoma are round, small, and densely hyperchromatic. 
They are often rounder than the nuclei in benign prostatic secretory cells. 
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2. Atrophic prostate cancers  
They are uncommon and may be seen as a benign lesion on needle 
biopsy. The cancer glands may be confused with benign atrophy 
because they have scant cytoplasm. The diagnosis is based on a 
number of features. They are these carcinomas displays an infiltrative 
growth pattern, with atrophic glands with mixture of larger benign 
glands. But, benign atrophy usually has a lobulated pattern. Atrophic 
prostate carcinoma has significant cytologic atypia, nuclear 
pleomorphism and prominent nucleoli.At last, atrophic prostate 
carcinoma is frequently intermixed with non atrophic ordinary 
prostate carcinoma. 
3.Pseudohyperplastic prostate cancer 
Resembling benign prostatic glands, pseudohyperplastic 
prostate carcinoma glands are large with branching and papillary 
infoldings
19,20
. However, the malignant glands are much more closely 
packed than benign glands, and they display malignant nuclear 
features typical of prostate carcinoma. The diagnosis of pseudohyper-
plastic prostate carcinoma on needle biopsies is often difficult and 
requires immunohistochemistry. This confirms that basal cells are 
absent. Pseudohyperplastic prostate carcinoma, inspite of its benign 
appearance, can be seen with typical intermediate-grade cancer. 
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Aggressive behavior can be noted. 
When composed of severely dilated glands with abundant 
cytoplasm, a pseudohyperplastic adenocarcinoma variant may be difficult 
to diagnose as malignant. It can be identified by numerous large glands 
with abundant cytoplasm, with straight even luminal borders that are 
almost back-to-back. Cytologic atypia in some of these specimens also 
distinguishes them. 
Atrophic adenocarcinoma of the prostate and Pseudohyperplastic 
adenocarcinoma are less commonly (62 – 77%) positive for AMACR.22  
Mucinous (Colloid) Carcinoma. 
Colloid  carcinoma is defined as a cancer in which 25 % or more of 
the tumor consists of abundant extracellular mucin. Prostate 
carcinoma with less than 25 % mucinous component should be 
classified as having mucinous features. Prostate cancer with 
intraluminal mucin without extracellular mucin is not considered as 
mucinous prostate carcinoma. The average age for colloid prostate 
carcinoma is similar to that for the ordinary prostate carcinoma, even 
though the clinical staging at presentation is frequently advanced, or 
metastatic disease. Microscopically, tumor cells float in lakes of 
extracellular mucin that are sharply demarcated from the 
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stroma.Tumor cells are arranged in cribriform pattern, cords, strands, 
acini, or tubules. Cytologically, they appear bland with infrequent 
prominent nucleoli. 
Signet-Ring-Like Carcinoma
35
. 
Defined as 25 % or more of tumor mass consisting of signet-
ring-appearing cells, this histologic variant is a rare entity with 
anaggressive clinical course. Microscopically, the signet ring-like 
tumor cells display displacement of nuclei and clear cytoplasmic 
vacuolar indentation. In majority of cases, these vacuoles contain 
lipid rather than mucin, as with true signet cells. The cancer cells 
grow as single cells, in small clusters and in sheets. They are 
invariably mixed with ordinary acinar prostate carcinoma 
components. PSAP and PSA Immunostains are positive in most cases. 
Stains for CK7, CK20, and HMWCK are negative in all cases. Before 
establishing a diagnosis of prostatic signet-ring carcinoma, a 
metastasis from other anatomic sites, including stomach, lung, colon, 
and pancreaticobiliary system, must be excluded. On the other hand, a 
prostatic signet- ring carcinoma should be considered when one 
encounters a signet-ring-cell carcinoma of unknown primary, 
especially if mucin stains are negative. 
Sarcomatoid Carcinoma (Carcinosarcoma).  
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Sarcomatoid prostate carcinoma  shows both malignant spindle 
cell and epithelial elements. It may be a de novo diagnosis, or patients 
may have a past history of prostate carcinoma post hormonal or 
radiation ablation treatment or both. Serum Prostate Specific Antigen 
is often normal in many cases, despite the frequent presence of nodal 
and distant metastases. The 5-year survival rate is less than 40%. 
Histologically, sarcomatoid prostate carcinoma is biphasic, with 
variable Gleason patterns seen in the gland component and a 
sarcomatoid component often exhibiting nondescript malignant 
spindle cell proliferation. Specific mesenchymal differentiation can 
also be present, including osteosarcoma, chondrosarcoma, and 
rhabdomyosarcoma. Immunohistochemically, the epithelial elements 
are positive for PSA and/or pancytokeratins, whereas the sarcomatoid 
elements react with corresponding mesenchymal differentiation 
markers and express cytokeratins in a variable manner. 
The reasons why the small focus in needle biopsies may not be 
conclusive of cancer are: 
1. Decreased number of minimally atypical glands 
2. High-grade PIN 
3. Difficuty in ruling out adenosis 
51 
 
4. Difficulty in differentiating atrophic cancers from atrophy  
  5. Inflammation associated causing reactive atypia 
  6. Distortion of tissue by crush artifact 
Prostate-specific Antigen (PSA)  
It is an important screening method for the detection of Prostatic cancers. 
Normal PSA levels are 2 -4 ng/ml. It increases with age. The following 
table shows the age specific reference values. 
IMMUNOHISTOCHEMISTRY 
 Prostate-specific Antigen (PSA) 
58,59 
It is detected in secretory cells of benign prostate glands in all 
anatomic zones, but not in seminal vesicle/ejaculatory duct 
epithelium, basal cells, or prostatic urothelial cells. Most prostate 
carcinomas also express PAS, although there is considerable 
intratumoral and intertumoral heterogeneity, and the expression is 
decreased in a minority of high-grade prostate carcinoma. After 
androgen deprivation and radiotherapy, some cancers can lose PSA 
expression. PSA immunoreactivity can be detected to variable degrees 
in some nonprostatic tissues and tumors, including urethral and 
periurethral glands, cystitis cystic and glandularis, urachal remnants, 
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bladder adenocarcinoma, and extramammary Paget‟s disease of the 
penis. 
Cytokeratins
58 
Basal and benign secretory prostatic cells are immunoreactive 
for antibodies to low-molecular-weight and broad-spectrum 
cytokeratins (CKs). Negative staining for both CK7 and CK20, which 
is typical of prostate cancer, is useful to differentiate prostate 
carcinoma from urothelial carcinoma, which is typically positive for 
both markers. 
Basal Cell Marker
36,54 
HMWCK is expressed not by secretary cells, only by prostate 
basal cells. It is identified by 34βE12 antibody clone. The clone 
identifies CK1, CK5, CK10, and CK14, or the antibody cocktail that 
recognizes CK5 and CK6. Basal cell layer is invariably not seen in 
Prostate carcinoma. Thus it is negative for HMWCK. A diagnosis of 
prostate cancer is supported by the absence of a basal lining. It is 
shown by lack of immunostain for HMWCK  
However, prostate carcinoma can occasionally contain sparse 
tumor cells positive for 34βE12. They may not be in a basal cell 
distribution, especially after radiation or hormonal therapy. Spread of 
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prostate cancer intraductally or benign entrapped glands may also be 
mistaken as residual cells in prostate carcinoma. Conversely, some 
benign conditions, including partial atrophy and adenosis (atypical 
adenomatous hyperplasia) may at times have an absent or 
discontinuous basal lining of cells. 
p63
59 
p63 is a nuclear protein expressed in pseudostratified epithelia 
in their basal cells. It has similar diagnostic utility and pitfalls as 
HMWCK. Only very rarely, it shows variability in staining. This is 
particularly seen in TURP specimens affected by cautery artifact. 
Thus it is easily interpreted due to its sharp and strong nuclear 
staining. 
α-Methylacyl-Coenzyme A Racemase.36,54,59  
AMACR is an enzyme involved in the intermediates of bile acid 
metabolism and metabolism of fatty acids (branched-chain). It is 
overexpressed in the most of prostate cancers. Because of its 
intratumoral heterogenous patterns of expression, in only eighty 
percent of cancers, AMACR is positive. Numerous prostate 
carcinoma histologic variants, such as atrophic, foamy gland, and 
psedohyperplastic prostate carcinoma, exhibit decreased expression of 
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AMACR. It is not completely specific for prostate carcinoma. This is 
due to the reason that it is present in HGPIN (90%), partially atrophic 
glands, adenosis (17.5%), and at times, morphologically benign 
glands. AMACR is used as a confirmatory staining for prostate 
cancer, in combination with basal cell markers and H&E histology. 
Dual chromogen
36 
AMACR and basal cell markers can be combined together in a 
single immunostaining reaction. Such “cocktail” staining may be 
useful when carcinoma is present only in one tissue section for the 
work – up of a small focus. 
Presently, in diagnostically challenging prostate cases, Alpha-
Methylacyl- CoA- Racemase (AMACR) and basal cell markers are being 
used in addition to morphology. This has caused a rise in accuracy of 
diagnosis of prostate cancer across the world. 
 Basal cell markers: 
HMWCK (34βE12) and P63 and CK 5/6 are critical for 
demonstration of basal cells in benign glands. When they are seen, a 
invasive prostatic cancer diagnosis is very less likely. 
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34 β E12  
This is a high molecular weight cytokertin immunochemical 
marker.It binds to high molecular weight cytokeratin,intermediate 
filament, not in luminal cells of prostate but in the basal cells‟ cytoplasm. 
Interpretation
36 
It is interpreted as positive / negative and continous / discontinous  
Limitations :
36 
For the diagnosis of prostate cancer, many limitations are noted in 
using basal cell markers. Stressing on absence of basal cell staining, a 
negative finding, to decide on a positive diagnosis of cancer is the most 
important. Also, some of benign prostatic glands (5% - 23%),  some 
specimens of atrophy(23%), up to half of specimens of adenosis, 66% 
specimens of mesonephric hyperplasia, 44%-75% samples of 
nephrogenic adenoma may lack basal cell staining. This is the reason why 
negative basal cell marker immunostaining in singularity cannot 
conclusively pinpoint carcinoma. 
Ejaculatory duct epithelium and seminal vesicle are invariably 
positive for basal cell markers. But the status of Cowper‟s glands is 
contradictory. 
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 Hence, one must be cautious while reporting negative basal 
immunostains. They support the diagnosis of prostatic carcinoma along 
with the presence of appropriate H&E picture. The decisive one is that 
some high grade prostatic carcinomas are positive for basal cell markers.. 
They are commonly easily detected based on H&E picture. 
In addition, some cases of invasive acinar adenocarcinomas, in 1% 
of cases, harbor basal cells. A few of these could be flat HGPIN or cancer 
outpouchings of HGPIN glands. So, even though being very useful, basal 
cell markers are to be interpreted carefully in the diagnosis of cancer. The 
definitive criterion is that a detectable positive basal cell layer is absent. 
Also, false-negative staining of basal cells can occur in prolonged 
formalin fixation. 
CK 5/6 
CK 5/6 is a mesothelial cell marker. It is expressed normally by 
complex epithelium and also in mammary carcinomas, as well as bile 
tract, pancreatic and malignant mesothelioma. This antibody does not 
react with HPIN or prostatic tumoral cells but with prostatic basal cells. 
p63 antibody 
It is an antibody to basal cells of prostate. It has a critical role in 
development of the prostate. It is expressed in normal prostatic glands by 
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basal cells. Most cases (89–94%) of prostate cancer do not express p63. 
Immunostaining with p63 is very useful in suspicious prostate cases.  
AMACR
36,58 
Thus, a specific and sensitive positive immunohistochemical 
marker is necessary. This increases the accuracy in pathological diagnosis 
of prostate malignancies. Also known as p504 S or racemase, AMACR, is 
an enzyme identified recently by microarray and cDNA subtraction 
technology. It is invariably up regulated in prostate cancer, being a 
specific and sensitive IHC tool. 
       It is overexpressed in prostate cancer with marked differential 
staining between malignant and benign glands. It is highly sensitive and 
is seen in 75-95% in prostatic carcinomas.
45 
                 The AMACR gene product, in prostate cancer, was identified 
to be over expressed. This was identified with a small number of prostate 
adenocarcinoma samples in conjunction with high-throughput microarray 
analysis by complementary DNA library subtraction. It is a protein whose 
activity is increased in prostatic adenocarcinoma.  Its gene is located on 
5p13, and its product resides in peroxisomes and mitochondria. The 
protein has an important role in the β oxidation of bile acid intermediates 
and branched-chain fatty acids. Since beef and dairy products are the 
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major sources of  branched -chain fatty acids, their intake has been linked 
with an increased risk of prostate cancer. AMACR overexpression and 
diet have, in the natural history of prostate cancer, complementary roles.
25 
It has been recognized that AMACR is also expressed in the 
precursor lesion to prostate cancer, HPIN, and even in low grade PIN
34,38
. 
At the protein level, AMACR overexpression is tightly linked to prostate 
cancer. It occurs in almost all stages and grades and also in untreated and 
hormone-refractory patients. DNA microarray analyses have also found 
significant overexpression of AMACR in prostate carcinoma. 
  Interpretation
36,39 
           Positive staining of AMACR refers to diffuse dark or granular, 
luminal or cytoplasmic, but circumferential staining. From 0+ to 3+, the 
percentage positivity is graded as below:- 
                0% cells (negative, 0+) 
               1-10% cells (mild, 1+)  
               11-50% cells (moderate, 2+) 
               > 51% cells (strong, 3+) 
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            There should be no more than weak staining or 
noncircumferential partial staining in the surrounding benign prostatic 
glands . 
 Negative staining refers to focal or no staining, fine weak 
noncircumferential staining. 
Expression of AMACR in prostatic cancer is upregulated. About 
75-95% of prostate cancers in immunohistochemistry are positive for 
AMACR. Therefore, AMACR is used as a positive prostate cancer 
marker in combination with negative basal cell markers (p63 or high-
molecular-weight CK). This helps in the diagnosis of suspicious prostate 
needle biopsies. 
             A significant advantage of AMACR immunostain exists. A 
diagnosis of malignancy is based on a positive indicator; not based on 
loss of signal. 
Limitations:
14,36 
A few morphological variants of prostatic cancer are a serious 
diagnostic problem. In these cases, immunohistochemistry is specifically 
needed to clinch the diagnosis of carcinoma. They have been seen to 
express less AMACR reaction when contrasted with the more 
conventional cases. AMACR expression is found in 62-68% of foamy 
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gland carcinomas and ~ 70-77% of pseudohyperpalstic cancers. Added to 
prostate cancer, in 90% cases of HGPIN, AMACR positivity is seen. This 
proves that HGPIN should be excluded with care by the use of basal cell 
markers and morphology, before AMACR positivity is used to report the 
diagnosis of cancer. In HGPIN, AMACR positivity varies between strong 
and weak. AMACR expression is also identified in 18-58% cases of 
nephrogenic adenoma, in 4%-21% benign prostatic glands and in 18- 
27% cases of adenosis.
39 
So, even though AMACR is an immunohistochemical marker of 
use in prostate carcinoma, it has significant drawbacks. It is so stressed 
that AMACR is to be interpreted in the suitable morphological scenario 
and with combination of basal cell markers.  
The commonest reason for error in diagnosis in TURP and needle 
biopsies is that the malignant foci are very limited (3-10%). The 
important reasons for the difficulty in detecting limited prostatic cancer 
are listed below. 
Most importantly, for histopathological examination, there may 
only be a few acini seen in the limited number of carcinomatous glands. 
Also, for the detection of prostate carcinoma a single feature sufficient 
and specific is not available. It is based on a combination of cytological 
and architectural features and extracellular material such as crystalloids 
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or secretions tinged blue. Many of these microscopic diagnostic 
conditions may be seen in benign conditions of the prostate sometimes. 
Added to that, the consequences may be very serious such as radiation 
exposure, unnecessary prostatectomy or delay in effective treatment when 
associated with a false negative or positive diagnosis. Various cases with 
change of diagnosis to malignant/premalignant from benign are 
underdiagnosed because of the presence of limited adenocarcinoma
36
. 
Also, causes of error are inflammation, missing out on HGPIN (not 
judiciously looking at high power), and diagnostic mistakes with benign 
mimics of carcinoma.
40 
In nonspecific staining of carcinomatous cells by basal cell 
markers, a few methods of antigen retrieval are implicated. Nonspecific 
tumor cell immunoreactivity is noted in the hot plate antigen retrieval 
method. But, for the overall staining, it is better than others. The 
microwave retrieval and pepsin predigestion methods did not cause this 
condition, however some benign basal acinar cells did not stain with these 
methods. 
 Uncommonly, HMWCK is expressed in high grade prostate carcinomas. 
But it is not a diagnostic problem usually, since malignant cells are 
positive for AMACR. 
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 Vincent et
28
 al in his study stated that p504s was a highly sensitive 
and specific marker for prostate cancer. AMACR is extensively 
upregulated at the transcript and protein levels in HPIN and 
adenocarcinoma. 
Xu et al
10
, in conjunction with microarray high-throughput 
screening, using cDNA library subtraction, discovered 3 proteins  - 
P504S, P503S, and P510S, specific for  carcinoma to differentiate 
between malignant and benign prostate tissue. 
          Xu et al
10
 also stated that a 382-amino-acid protein is P504S. It is 
actually AMACR - human α-methylacyl coenzyme A racemase. AMACR 
plays a role in the β-oxidation of fatty acid derivatives and branched-
chain fatty acids. P504S mRNA - messenger RNA is overexpressed in 
approximately 30% (microarray screening) to 60% (quantitative 
polymerase chain reaction analysis) of prostate cancers. It is undetectable 
or low in normal prostate tissues. 
            In 2001, Jiang et al
5
 stated that P504S (AMACR) was, for prostate 
tumors, a new immunohistochemical marker.  P504S/AMACR is a 
marker with high sensitivity for prostate carcinoma. In 92% of cases, a 
diffuse staining pattern (>75% cancer positive) was visualised without 
regard to Gleason score. P504S/AMACR in high-grade prostatic 
intraepithelial neoplasia (PIN) was also strongly positive. 
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The study also reported that of P504S/AMACR and high-
molecular- weight cytokeratin expression was mutually exclusive. 
AMACR/ P504S is a marker for prostate cancer with high specificity. 
Benign tissue samples of prostate (88%), including benign prostate tissue 
surrounding carcinomas were completely negative for P504S/AMACR in 
contrast to cancers. Therefore, it was showed that, the AMACR/ P504S 
staining pattern must be an adjunct to distinct benign and malignant 
glands; and it is to be applied in conjunction with the histological criteria. 
              Luo et al,
12
 in his study assessed the association of the 2 
antibodies.p63 as a negative marker and p504s as a positive marker were 
studied. This significantly helps the diagnosis of prostate carcinoma. It 
causes an increase in diagnostic precision, a decrease in the false 
negatives risk, and increased specificity and sensitivity in detecting 
prostate cancers. 
          In 2002, Rubin et al
53
 confirmed increased AMACR expression in 
prostate carcinoma with polyclonal antibody to AMACR and cDNA 
microarrays. Rubin et al reported that in three of four DNA microarray 
analyses (128 samples) independently and microarray tissue specimens, 
including 17 metastatic prostate cancers, significant AMACR 
overexpression in prostate carcinoma was note. 
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Hameed et al
33
 stated in his study that Basal cell markers like 
antibodies directed against cytokeratin 5 and 6 or p63 and 34BetaE12 
antibody help to demonstrate basal cells. Their presence is against a 
diagnosis of invasive prostatic cancer. Although, many benign mimickers 
of PC, including nephrogenic adenoma, atypical adenomatous 
hyperplasia (AAH), atrophy and mesonephric hyperplasia, with these 
markers, can stain negatively, a negative basal cell marker immunostain 
cannot singularly rule out a diagnosis of benignancy. Despite the fact that 
there are instances in literature of high grade PC that, with a few of the 
basal cell markers, stain focally; these are usually easily detected based 
on microscopic appearances. They are less likely to be confused with 
such benign mimickers.  
(AMACR) - Alpha-methylacyl-coenzyme-A racemase is a 
sensitive marker of Prostate cancer (except for a few rare variants: foamy 
gland, atrophic, and pseudohyperplastic variants). It‟s detection in 
atypical prostatic lesions by immunohistochemistry is very helpful in 
confirming a diagnosis of prostate cancer. AMACR expression may also 
be seen in prostatic atrophy, high grade prostatic intraepithelial neoplasia 
(PIN), benign prostatic glands and AAH. Therefore, a report of Prostate 
Cancer must not be based singularly on a positive immunostain of 
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AMACR. This is more important in conditions where the luminal staining 
is noncircumferential and/or weak.  
Luo et al 
12
 discovered that out of all histologically normal 
prostatic epithelium, < 4% showed positive staining for AMACR; while 
in prostate cancers, > 95% stained positively. They also showed 81% and 
93% positivity of AMACR in thirty two metastatic prostate cancers from 
non–hormone-refractory disease and fourteen hormone-refractory 
metastatic prostate cancers, respectively. They stated finally that 
AMACR is a positive immunohistochemical marker that adds advantage 
to concretely diagnose prostate cancer, along with the traditional basal 
cell stains. 
Beach et al
29
  in his study from 405 prostatic specimens, showed  
that P504S monoclonal antibody  was positive in 376 prostate needle 
biopsy specimen. Also reported that  in biopsy specimens,82% of 186 
cases showed  positivity for AMACR immunostaining , but foci of benign 
prostate epithelium showed only 21% positivity.As well as they show 
faint,focal and non circumferential  staining. The most specific staining 
pattern of AMACR is diffuse and circumferential cytoplasmic staining in 
prostate carcinoma and no staining in benign prostate tissue. Positive 
staining was not found in the transitional metaplasia, specific small gland 
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proliferation of postatrophic hyperplasiaas well as in basal cell 
hyperplasia. 
Leav et
20
 al in his study showed that AMACR (P504S) expression 
in prostate carcinoma is common in the transition zone. All 25 cases in 
the study with Gleason grade 1 carcinoma were positive for AMACR.But 
compare to high grade carcinoma  staining was less intense in grade 1. 
     Magi-Galluzzi et al
25
 studied numerous cases (209 cases), all are 
needle biopsy  with minimal foci (<5% of a core) of prostate cancer. 88% 
were positive for AMACR in the small foci of prostate cancer. They  also 
studied that the among the different groups the sensitivity varied.80 % to 
87% for cases from outside institutions and100% for the in-house cases 
.They were chosen to include the differences in processing and fixation in 
various pathology laboratories. Eventhough it is essential to recognize 
AMACR  negative staining  in some minimal cancers, they came to 
conclusion  that from the needle biopsy specimen  positive staining of 
AMACR may increase the range of confidence in establishing a definitive 
diagnosis of malignancy. 
 (1) If small, focal atypical glands stain with basal cell markers but not 
with AMACR/P504S, the diagnosis is benign.  
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(2) When atypical glands are positive for 34βE12/p63 and 
AMACR/P504S, malignancy can be ruled out. The differential diagnoses 
include high-grade PIN, adenosis, and even some benign glands based on 
the findings on H&E staining. 
 (3) If small atypical glands, excluding high-grade PIN and nephrogenic 
adenoma, are negative for basal cell markers but positive for 
AMACR/P504S, a malignant diagnosis is established. 
(4) In the scenario that small atypical glands are negative for 34βE12/p63 
and AMACR/P504S, the diagnosis might be malignant or benign.  
In their study, the likelihood of negative staining of both 34βE12/p63 and 
AMACR/P504S in small focal carcinoma in needle biopsy specimens is 
rare (<6%).  
       Magi-Galluzzi et al
25
 reported a variable sensitivity (80%-100%) of 
AMACR for the diagnosis of minimal prostatic cancer. They emphasize 
that it is important to recognize that some small focal cancers might be 
negative for AMACR/P504S.
44,45
 
In a recent study, Jiang et al
5
 examined, on prostate needle biopsy 
specimens, 41 foci of “atypical cases” with a AMACR / P504S 
combination and 34βE12 stains. The study described that when the 
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antibodies combination was used, more than half the suspicious atypical 
foci were diagnosed definitively.  
Oppenheimer et al
30
 showed patchy basal cells in 12 cases stained 
for high-molecular-weight cytokeratin (HMWCK). Hence, partial atrophy 
can sometimes cause diagnostic challenges in prostate needle core biopsy 
specimens. 
 A recent report by Herawi et al
25
 identified 567 atypical but benign 
foci in specimens from 345 patients received in consultation. The authors 
found that partial atrophy was the most common mimicker of 
adenocarcinoma (203 of 587 cases [34.6%] 
Jiang, Zhong et al 
5,30
in his study, described cases with a small 
focus of prostate cancer (73) measuring ≤1 mm and benign prostatic 
cases (69), totalling 142 needle biopsies. They were studied by using 
immunohistochemistry for (34βE12) - high molecular weight cytokeratin 
and P504S. Out of 73 cases, 69  (94.5%) of carcinoma showed P504S 
immunoreactivity. It was not seen in any benign prostates (none out of 
69) or benign glands adjacent carcinomatous glands. In all 73 cases, 
immunostaining with 34βE12 demonstrated that in the focus of 
carcinoma, basal cells were absent. Its significant diagnostic value in 
pathologic practice was confirmed by the high sensitivity and specificity 
of P504S in the diagnosis of minimal prostate cancer. Utilising a 
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combination of 34βE12 and P504S on needle biopsy helps the detection 
of limited prostate cancer. 
Vogel and Gown
50
 described the utility of 34βE12, a anti-high 
molecular weight cytokeratin monoclonal antibody. This was applied to 
mark prostate‟s basal cells. They were described to be characteristic of 
benign glands which retain the layer of basal cells. In a bigger series, 
Epstein and Wojno to diagnose adenocarcinoma used 34βE12 in 
suspicious glands detected in prostate needle biopsy series. 
Jiang et al
5
 stated that HMWCK (34bE12) and AMACR 
immunohistochemistry, in the study of 41 atypical small acinar 
proliferation (ASAP) foci caused a 76% agreement rate between the three 
pathologists involved. 
        Zhou et al 
13
 demonstrated that based on a positive AMACR 
immunostain, out of 115 biopsies of prostate detected by an expert 
pathologist, as atypical, 34 (30%) were labelled a final diagnosis of 
cancer. 
Browne et al 
21
 described that the utility of a combination of both 
AMACR and basal cell antibody immunostain resolved the diagnosis in 
86/123 (70%) of suspicious prostate biopsies. 
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 Sanderson et al 
22
 used AMACR/ p63 combination to redesignate 2 of 7 
(29%) atypical needle biopsies as prostate cancer. 
             Kunju et al 
14
 were able to resolve 27 of 29 (93%) atypical 
biopsies due to immunostaining with basal cell marker and AMACR. 
             Tara Jane Browne
21
 showed that in microscopically difficult 
cases, utilising combination of stains can be a helpful approach since it 
increases the chance that a conclusive diagnosis can be arrived at while 
decreasing the possibility of an inconclusive diagnosis. But, a 
disadvantage of the said method is the loss of tissue in such small lesions, 
hinting that combining BCC and AMACR on a single slide will be better 
than using either separately.   
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MATERIALS & METHODS 
Study Design : 
              Prospective study 
Study Period :  
           From August 2011- July 2012 
Study Place : 
           Coimbatore Medical College Hospital, Coimbatore 
Sample size :  
              A total number of 37 cases 
 From case records, brief clinical data were collected, 
which included age, presenting complaints, digital rectal examination 
(DRE) findings, serum PSA levels and clinical diagnosis.                                                                                                                         
              The following inclusion and exclusion criteria were adopted. 
Inclusion criteria 
1. All prostatic specimens- needle biopsies, TURP- 
transurethral resection of prostate and radical 
prostatectomy specimens. 
2. Patients in all age groups 
72 
 
Exclusion criteria 
1. Ill fixed samples  
2. Inadequate samples 
 A proforma was used to document demographic data, age, 
dietary habit, clinical presentation and previous history as given in 
Annexure – 1. 
The study was conducted in the same hospital.  
Methods: 
Among the total cases received in the department of pathology of 
our hospital during study period, 37 cases were taken into study as per 
inclusion criteria and 3 cases were eliminated from the study because of 
insufficient material and as the biopsy was non representative. 37 cases 
were finally evaluated further. Included were 29 needle biopsies and 8 
TURP specimens. 
 The received samples were then fixed in 4% formalin, 
embedded in paraffin and stained with H&E.    
After eosin and hematoxylin staining all slides were reviewed by 
pathologists and assigned to the following groups - Benign prostatic 
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hyperplasia (10), Basal cell hyperplasia (1), PIN (5), malignant (20) and 
suspicious (1). 
    There are 37 cases.They  consisted of 29 needle biopsies and 8 TURP 
specimens. The age group were differed between 48 and 85 years.  
The value of Serum Prostate  specific antigens was available for 3 
cases and ranged between 7 and 100. 
PROCEDURE OF IMMUNOHISTOCHEMISTRY 
The blocks from control and selected cases were cut and mounted 
on poly l- lysine coated glass slides .Blocking of Endogenous peroxidase 
activity was done by 0.3% hydrogen peroxide in methanol, freshly 
prepared, for twenty minutes. Then, epitope retrieval by heat was 
performed by using buffer of Tris EDTA at pH 9. Immunohistochemistry 
was done by utilising a monoclonal anti-HMWCK antibody (clone no 
34βE12 of 1:50 dilution) and a rabbit monoclonal anti-AMACR antibody 
(p504 S, clone no 13H4 of 1:50 dilution). 
IMMUNOHISTOCHEMISTRY 
METHOD: 
                 Two-step indirect technique. 
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PRINCIPLES OF THE PROCEDURE: 
Using a two-stage process, antigens in cells and tissues were 
detected. The first was the binding to specific epitopes of the primary 
antibody. Second was a calorimetric reaction to detect the binding. 
Sections of tissue were fixed and attached to slides. The paraffin-
embedded sections were then dewaxed. Antigen retrieval procedure was 
done. This consisted of the heating in microwave of formalin-fixed tissue 
in an aqueous solution. It recovered full antigenicity with a most of the 
antibodies. These also included cases that were formerly unreactive with 
formalin-fixed tissue. Subsequently, the tissue sections were treated with 
Peroxide-Block and Power-Block for blocking endogenous peroxidise nd 
non-specific protein-protein interactions, respectively. 
REAGENTS USED 
1) Peroxide Block: 3%hydrogen peroxide in water.Power 
Block Reagent: A highly effective universal protein 
blocking reagent. Contains casein and propriety additives 
in PBS with 15mM sodium azide. 
2) Chromogen: DAB-3,3‟-diaminobenzidine. 
3) Liquid DAB Substrate: Comprises Tris buffer containing 
the peroxide and stabilizers. 
4) Super Enhancer Reagent. 
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5) Poly-HRP Reagent. 
6) Counter stain: Mayer‟s Hematoxylin. 
7) Buffer solutions:  
           TRIS BUFFER: (ph -7.6) 
                         TRIS Buffer salt : 0.605 gm 
                         Sodium chloride : 8 gm 
                         Distilled water : 1000 ml 
                         1N Hydrochloric acid : 3 ml 
            CITRATE BUFFER: (ph-6.0) 
                         Trisodium citrate : 2.94 gm 
                         Distilled water : 1000 ml 
                         1 N Hydrochloric acid : 5 ml 
            TRIS EDTA: (ph-9.0) 
                         TRIS Buffer salt : 6.05 gm 
                         Disodium EDTA : 0.744 gm 
                         Distilled water : 1000 ml                      
PROCEDURE: 
1) Sections were deparaffinised in xylene for 30 minutes. 
2) Washed in absolute alcohol for 5 minutes with 2 
changes. 
3) Slides were then washed for 10 minutes in tap water  
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4) Rinsed for 5 minutes in distilled water. 
5) Antigen retrieval was done by placing the slides with 
appropriate buffer solution in microwave : Medium-10 
minutes: High-10 minutes. 
6) They were then cooled to room temperature and rinsed 
in distilled water. 
7) Washed in TBS buffer for 5 minutes with 2 changes. 
8) Treated with Peroxide Block for 10 minutes. 
9) Washed in TBS buffer for 5 minutes with 2 changes. 
10) Treated with Power Block for 10 minutes. 
11) Slides were drained and covered with primary 
antibody (supplied from DAKOCYTOMATION) for 2 
hours. 
12) Washed in TBS buffer for 5 minutes with 2 changes. 
13) Slides were covered with Super Enhancer for 30 
minutes. 
14) Washed in TBS buffer for 5 minutes with 2 changes. 
15) Poly HRP reagent was applied and left for 30 minutes. 
16) Washed in TBS buffer for 5 minutes with 2 changes. 
17) Treated with DAB Chromogen with Substrate buffer 
for 5 to 8 minutes. 
18) Washed in TBS for 5 minutes with 2 changes. 
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19) They were then washed for 5 minutes in tap water. 
20) They were counterstained for 1 minute with Mayer‟s 
Hematoxylin. 
21) Washed for 5 minutes in tap water. 
22) Slides were air dried and mounted with DPX. 
Tumor cells were scored positive if there was golden brown 
cytoplasmic, nuclear or membrane staining in the neoplastic cells. 
Negative diagnosis was made when no golden brown staining was noted. 
Interpretationof Immunohistochemistry: 
Criteria for positive/ negative staining 
AMACR
36 
Positive staining refers to granular or dark diffuse, luminal or 
cytoplasmic staining. The percentage positivity was graded between 0+ 
and 3+ as below:- 
 negative (0+, 0%cells) 
 mild (1+,5-10% cells) 
 moderate (2+,11-50% cells) 
 strong (3+,51% cells) 
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Negative staining refers to focal or no staining, fine or weak and  
partial or noncircumferential staining. 
34βE1236 
The basal cell marker of benign prostatic glands, High molecular 
Weight Cytokeratin, was interpreted as positive/negative cytoplasmic or 
membrane staining  and discontinuous/continuous staining. 
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OBSERVATION AND RESULTS  
A total of 37 cases were selected as per Inclusion and Exclusion 
criteria. Among the 37 cases, 2 cases were negative for both AMACR and 
34βE12. It could be because of improper fixation - overfixation or 
underfixation.   
Considering the clinical details and morphology, in the present 
study of Immunohistochemistry with AMACR and HMWCK, 35 cases 
were chosen for evaluation. 
Prostate carcinoma : 
17 out of 19 cases categorised as prostatic carcinoma showed 
moderate to strong positive cytoplasmic staining of AMACR in 
malignant areas, but not in any benign glands adjacent to that. 2 out of 19 
cases of prostatic carcinoma showed negative staining with AMACR. 
Immunostaining with 34βE12 confirmed that basal cells were 
absent in the cancer focus in all 19 cases of prostatic carcinoma. 
Prostatic Intraepithelial Neoplasia 
3 out of 5 cases categorised as prostatic intraepithelial neoplasia 
showed focal, weak and granular cytoplasmic positivity with AMACR. 
Added to it, staining with 34βE12 highlighted the basal cell layer in 3 out 
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of 5 cases. Compared to prostate cancers, a weaker intensity of AMACR 
expression was noted in high grade PIN cases. 
Atypical focus suspicious of malignancy 
1 case categorised as ASAP , showed positive staining in luminal 
cells by AMACR and negative staining with 34βE12 in basal cells. Thus 
it was diagnosed as positive for malignancy. 
Benign prostatic Hyperplasia 
Among 9 cases categorised as Benign prostatic Hyperplasia ,8 
cases showed positivity for HMWCK in benign glands and 1 out of 9 
showed negativity for HMWCK. 
All the 9 cases of benign prostatic hyperplasia showed negativity 
for AMACR. 
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INCIDENCE OF PROSTATIC LESIONS 
Totally 50 specimens of prostate were received in the Department of 
Pathology during the study period. 
TABLE 1: INCIDENCE OF VARIOUS PROSTATIC LESIONS 
    PROSTATIC LESIONS No of cases PERCENTAGE 
BPH 24 48% 
Basal cell hyperplasia 1 2% 
Atypical foci 1 2% 
PIN 5 10% 
Prostatic cancer 19 38% 
Total   50 100% 
The incidence of Benign Prostatic Hyperplasia was highest in the 
study with 24 cases contributing to 48%, followed by 19 cases of 
Prostatic carcinoma comprising 38% of cases.  Prostatic Intraepithelial 
Neoplasis comprised 10% of the cases. Basal cell hyperplasia and 
Atypical foci were with 1 case each. 
CHART I :  INCIDENCE OF VARIOUS PROSTATIC LESIONS 
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TABLE 2: AGE DISTRIBUTION OF PROSTATIC CARCINOMAS 
AGE (years)      NO.OF CASES PERCENTAGE 
60-65 3 15.78% 
66-70 5 26.31% 
71-75 9 47.36% 
75-80 2 10.52% 
Total 19 100% 
In the present study, the incidence of Prostatic carcinoma was 
highest in the age group of 71 to 75 years, comprising about 48% of the 
cases followed by 66 to 70 year category with 5 cases (26 %),60-65 
years(16%),75-80(11%).  
 
 
CHART II: AGE DISTRIBUTION OF PROSTATIC 
CARCINOMAS 
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TABLE 3: DISTRIBUTION OF PROSTATIC CARCINOMA WITH 
REFERENCE TO GLEASON’S SCORE 
Gleason score No of cases Percentage 
6 5 26.31 % 
7 6 31.57% 
8 4 21.05% 
9 3 15.78% 
10 1 5.26% 
Total 19 100% 
Out of the 19 cases of prostatic carcinoma, 6 cases (31.5%) were of 
 grade 7 and 5 cases (26 %) were of Grade 6. Grade 8, 9 and 10 had 
 4(21%), 3(16%) and 1(5%) cases respectively. 
 
CHART III: DISTRIBUTION OF PROSTATIC CARCINOMA 
WITH REFERENCE TO GLEASON’S SCORE 
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TABLE 4 - EXPRESSION OF AMACR 
 No of cases AMACR 
positive 
AMACR 
Negative 
Prostatic 
Carcinoma 
19 17 2 
PIN 5 3 2 
ASAP 1 1 0 
BCH 1 0 1 
BPH 9 0 9  
BPH - Benign Prostatic Hyperplasia 
BCH - Basal Cell Hyperplasia 
PIN - Prostatic Intra epithelial Neoplasia 
ASAP - Atypical Small Acinar Proliferation 
 
CHART IV: EXPRESSION OF AMACR 
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TABLE 5 - EXPRESSION OF 34ΒE12 
 No of cases Positive Negative 
Prostatic 
Carcinoma 
19 0 19 
PIN 5 +/-3 2 
ASAP 1 0 1 
BCH 1 1 0 
BPH 9 8 1 
+- indicates focal and discontinuous positivity 
BPH - Benign Prostatic Hyperplasia 
BCH - Basal Cell Hyperplasia 
PIN - Prostatic Intra epithelial Neoplasia 
ASAP - Atypical Small Acinar Proliferation 
 
CHART V - EXPRESSION OF 34βE12 
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TABLE 6: AMACR GRADING  IN PROSTATIC CARCINOMA 
 
Grading No of cases Percentage (%) 
0(Negative) 2 10.5% 
1(Weak) 1 5.25% 
2(Moderate) 2 10.5% 
3(Strong) 14 73.6% 
Total 19 100% 
Grade 3 positivity of AMACR was observed in 14 cases of Prostatic 
carcinoma ,Grade 2 in 2 cases ,Grade 1 in 1 case. 
 
 
CHART VI: AMACR GRADING  IN PROSTATIC CARCINOMA 
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Table 7 - AMACR EXPRESSION  
 Prostate carcinoma BPH 
Positive 17 0 
Negative 2 9 
 
Detection of prostatic carcinoma by AMACR 
Sensitivity : 89.47% 
Specificity : 100% 
 
 
CHART VII: AMACR EXPRESSION 
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TABLE 8 :34βE12 EXPRESSION 
 BPH Prostate carcinoma 
Positive 8 0 
Negative 1 19 
 
Detection of prostatic carcinoma by 34βE12   
Sensitivity : 100% 
Specificity : 88.88% 
 
 
CHART VIII: 34βE12 EXPRESSION 
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TABLE 9:COMPARISON OF AMACR AND 34ΒE12 IN 
DETECTING  PROSTATE CARCINOMAS 
 Sensitivity Specificity 
AMACR 89.47% 100% 
34βE12 100% 88.88% 
 
 
CHART IX: COMPARISON OF AMACR AND 34ΒE12 IN 
DETECTING PROSTATE CARCINOMAS 
 
 
 
TABLE 10: PERCENTAGE POSITIVITY OF AMACR & 34βE12 
 No of cases AMACR 
Positive 
34βE12 Positive 
PC 19 17/19 (89.47%) 0/19(0%) 
Benign 9 0/9 (0%) 8/9(88.8%) 
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TABLE 11:COMPARISON OF AMACR INDICES IN VARIOUS  
STUDIES 
 Total no of PC 
cases 
AMACR 
positive  
Sensitivity  
Sung et al 49 35 71% 
Zhong jiang (1) et 
al 
73 69 95% 
Victor et al 113 108 96% 
Kumerasan et al 25 23 92% 
Present study 19 17 90% 
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TABLE 12: COMPARISON OF 34ΒE12 INDICES IN VARIOUS 
STUDIES 
 
 Total no of PC 
cases 
34βE12 positive Specificity  
Sung et all 49 0 100% 
Victor et all 113 5 93% 
Zhong jiang  82 0 100% 
Kumerasan et al 25 4 84% 
Present study 19 0 100% 
 
 
 
CHART  XI COMPARISON OF 34ΒE12 INDICES IN VARIOUS 
STUDIES 
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IMAGES   
 
             Fig.1.H&E shows Benign prostatic Glands with secretions inside it 
                      with fibromuscular stroma .10X 
 
 
 
 
           Fig.2. Continous 34βE12 positivity of basal cell layer in  Benign prostatic 
                    Glands.10X 
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     Fig.3.H&E shows  magnified view of Benign prostatic Glands 
              40X 
 
 
 
Fig.4. Continous 34βE12 positivity of basal cell layer in  Benign 
prostatic  Glands.40X 
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     Fig.5.H&E shows benign prostatic glands in 
   needle biopsy. 10X 
 
 
 
 
Fig.6.34βE12 shows continous positivity of basal cell layer in 
    benign  prostatic glands. 10X 
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Fig.7.H&E shows Benign Prostatic Glands in needle biopsy.10X 
 
 
 
 
 
Fig.8.Continous 34βE12 positivity of basal cells in benign prostatic glands.10X 
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Fig.9.Continous 34βE12 positivity of basal layer in benign prostatic glands.40X 
 
 
 
 
 
Fig.10.Continous 34βE12 positivity of basal layer in benign prostatic glands.40X 
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Fig.11.Continous 34βE12 positivity of basal layer in benign prostatic glands.10X 
 
 
 
Fig.12.High power view of Continous 34βE12 positivity of basal layer 
 in benign prostatic glands.40X 
 
98 
 
 
     Fig.13.H&E of Basal cell Hyperplasia shows multilayering of 
                 basal cells .10X  
 
 
 
 
     Fig.14.Continous positivity of 34βE12 in Basal cell Hyperplasia 
                shows multilayering of basal cells .10X  
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     Fig.15.Continous positivity of 34βE12 in Basal cell Hyperplasia 
                shows multilayering of basal cells .40X  
 
 
 
 
     Fig.16.Continous positivity of 34βE12 in Basal cell Hyperplasia 
                shows multilayering of basal cells .40X  
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Fig .17.H&E shows Low grade Prostatic Intraepithelial Neoplasia.10X 
 
 
 
Fig .18.Discontinous 34βE12 positivity of basal cell layer in Low grade 
Prostatic Intraepithelial Neoplasia.10X 
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Fig .19.Weak & Non-circumferential positivity of AMACR in luminal 
epithelial cells in Low grade Prostatic Intraepithelial Neoplasia.10X 
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Fig .20.Weak & Non-circumferential positivity of AMACR in luminal 
epithelial cells in Prostatic Intraepithelial Neoplasia.10X 
 
 
 
 
Fig .21.Weak & Non-circumferential positivity of AMACR in    
luminal epithelial cells in Prostatic Intraepithelial Neoplasia.40X 
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           Fig .22.Continous, strong positivity of AMACR in  luminal epithelial  
cells in Prostatic carcinoma.10X 
 
 
 
 
Fig .23.Continous, Granular &Strong positivity of AMACR in  luminal 
epithelial cells in Prostatic carcinoma.40X 
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Fig .24.Continous 34βE12 positivity of basal cell layer and adjacent            
malignant foci shows negativity of 34βE12 in Prostatic carcinoma.10X 
 
 
 
 
Fig.25.Continous 34βE12 positivity of basal cell layer and adjacent            
malignant foci shows negativity of 34βE12 in Prostatic carcinoma.40X 
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Fig .26. Granular &Strong cytoplasmic positivity of AMACR in  
malignant epithelial cells & its absence in adjacent benign glands 
in Prostatic carcinoma.10X 
 
 
 
Fig .27. Granular &Strong cytoplasmic positivity of AMACR in  
malignant epithelial cells & its absence in adjacent benign glands 
in Prostatic carcinoma.10X 
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Fig.28. H&E shows Signet ring carcinoma of Prostate.10X 
 
 
 
 Fig.29.AMACR  shows strong and granular cytoplasmic positivity in 
Signet ring carcinoma of Prostate.10X 
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Fig.30. H&E shows High grade Carcinoma of Prostate in needle 
biopsy.10X 
 
 
 
Fig.31.AMACR  shows  diffuse ,strong and granular positivity of 
malignant foci in Carcinoma of Prostate.10X 
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Fig.32.AMACR  shows diffuse,strong and granular positivity 
 Carcinoma of Prostate in needle biopsy.40X 
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Fig .33. Granular &Strong cytoplasmic positivity of AMACR in  
malignant epithelial cells & its absence in adjacent benign glands 
in Prostatic carcinoma.10X 
 
 
Fig.34.AMACR  shows strong and granular positivity            
Carcinomaof Prostate in needle biopsy.10X 
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DISCUSSION 
 Some cases of needle biopsies are difficult in instances where only 
a few cancerous glands (minute carcinomas, small focus carcinomas) or 
benign mimics of cancer are there. 
Considering the histologic features, based on standard histological 
staining, an initial diagnosis of “atypical small acinar proliferation” may 
be done. The diagnosis of such inconclusive cases affects 1.5–9% of 
prostate biopsies.  
           In this present study, in the 19 cases of prostatic carcinoma, 
AMACR positivity was detected in 17 cases, showing positive 
cytoplasmic granular staining. All 19 cases showed negative basal 
staining with 34βE12 . 
         The sensitivity of AMACR was 17/19 (90%) and the specificity of 
34βE12 was 0/19 (100%). 
          Among the 10 benign cases including 1 case of basal cell 
hyperplasia, all the 9 cases stained positive with 34βE12 with a continous 
cytoplasmic positivity in basal cells. None of the above 10 cases were 
positive for AMACR staining.  
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     Detection of prostatic carcinoma by 34βE12 had a Sensitivity of 100% 
and Specificity of 88.88%. 
 The accuracy of AMACR in detecting prostatic carcinoma was 
 90 % ( 17 out 19 of cases) 
 The accuracy of AMACR in detecting benign prostatic lesions was 
100 % ( 9 out 9 of cases) 
 The accuracy of  34βE12 in detecting prostatic carcinoma was 
100 % ( 19 out 19 of cases) 
 The accuracy of 34βE12 in detecting benign prostatic lesions was 
88.88 % ( 8 out 9 of cases) 
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ALGORITHM FOR THE IMMUNOHISTOCHEMICAL 
MARKERS  
 
The observation and results of previously conducted study relevant 
to his study are discussed below. 
Vincent et al study
28
 stated that prostatic cells in high-grade PIN, 
expressed with an intracytoplasmic granular pattern, p504s in 20–80 % of 
cases. 
We also observed that this expression is generally weaker and 
more focal than the positivity of the tumoral prostatic glands. 
Vincent study 
28
 results confirms that p504s is absent in cases of 
transitional metaplasia, atrophy, basal cell hyperplasia and postatrophic 
hyperplasia. 
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In this study we also observed the absence of expression of p504s 
in cases of basal cell hyperplasia. 
Vincent‟s study28 indices in terms of specificity and sensitivity (95 
and 98%) are in concordance with the numbers described in literature. 
The combination of p504s and 34βE12 helps the confirmation of 
neoplastic transformation in the prostate gland; this has been stated by 
several groups as a helpful marker of tumoral prostatic cells in a 
diagnostic scenario. There is an increased specificity of up to 100% and 
sensitivity of up to 97%. This applies both in standard and tissue array 
biopsies. The results in this study are concordant with our study. 
Luo et al,
12
 stated in a simple assay that the two antibodies 34βE12 
and p504s, when associated or combined together, one (34βE12) as a 
negative marker and the other(p504s) as a positive marker, significantly 
helps the detection of carcinomatous prostate cells. This results in 
improved specificity and sensitivity, a rise in diagnostic precision, and a 
fall in the risk of false negatives. The results in this study are concordant 
with our study. 
Vincent‟s study28 states that out of the “atypical small acinar 
proliferation” group, 89.4% can be detected using a combination of the 
two antibodies.  It decreased the percentage of additional biopsies and 
inconclusive interpretations. 
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Zhiang Jiang
30
 in his study, reported that immunoreactivity with 
p504s was found out of 73 cases in 69 (94.5%) of carcinoma. It was not 
seen in any benign gland surrounding malignant glands or case of benign 
prostate (0 of 69) or. The 34βE12 immunostaining, in all 73 cases, 
confirmed that basal cells were absent in the carcinoma focus. The results 
in this study are concordant with our study. 
Luo et al
12
 stated that < 4% of histologically normal prostate 
epithelium was positive for AMACR, while > 95% of prostate carcinoma 
stained positively. The results in this study are concordant with our study. 
Victor et al
27
 showed that AMACR was positive in 88% cases of 
small foci of prostatic carcinoma. They found that among the different 
groups AMACR sensitivity varies:  80% to 87% for cases from outside 
institutions and 100% for the in-house cases. P504S immunostaining was 
found in (94.5%) 69 of 73 cases of  prostatic cancer but not in any benign 
glands adjacent to malignant glands and any benign prostates (0 of 69). In 
all 73 cases,the  basal cells  show absent 34βE12 immunostaining 
confirmed  the focus of carcinoma. The results in this study are 
concordant with our study. 
Beach et al 
29 
studied that (82%) that is153 of 186 biopsy 
specimens with prostate cancer shows positivity for AMACR.But only 
115 
 
21% of the  benign prostatic epitheliai cells  showed faint, focal,and 
noncircumferential staining . 
Rubin et al 
53 
showed that among 94 specimens of prostate needle 
biopsy, demonstrated 100% specificity and 97% sensitivity of AMACR 
in  prostate carcinoma detection. 
Sung MTJiang
43
 et al studied that basal cell markers ( p63 or 
34betaE12) were totally absent in all malignant acini. In (29%)  14 of 49 
cases of prostatic carcinoma cells failed to demonstrate AMACR 
expression . In the remaining cases of 35 (71%), positive immunostaining 
with variable intensities and percentages of cells of AMACR was seen. In 
benign gland,positive staining for AMACRs was not seen in any case. In 
all benign acini cases, basal cells were strongly stained by p63 with a 
mean positive percentage of 96%. The results in this study are concordant 
with our study. 
Victor et all
27
 in his study showed AMACR specificity ranges from 
79% to 100% and the sensitivity varies from from 82% to 100% 
Rubin et al
53
in his study showed that in 94 specimens of prostate 
needle biopsy ,AMACR has 100% specificity and 97% sensitivity in the 
detection of prostate carcinoma 
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The results and indices in this study are in conformity with the 
previously conducted studies.  
Thus it goes on to show that immunohistochemistry has a vital role 
in detection of morphologically difficult  prostatic lesions. 
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CONCLUSION 
               In the present study the incidence of prostatic carcinoma was 
common in the age group of 71-75 years. 
               Incidence of prostatic carcinoma was 38%, prostatic 
intraepithelial neoplasia was 10%, benign prostatic hyperplasia was 48% 
AMACR  grading:  
74% cases showed Grade 3 positivity 
10% cases showed Grade 2 positivity 
5% cases showed Grade 1 positivity 
10% cases showed Grade 0 positivity 
             The sensitivity of AMACR in detection of prostate carcinoma 
was 90% and specificity was 100%. 
             The sensitivity of 34βE12 detection of prostate carcinoma was 
100% and specificity was 89%. 
             Newer antibodies against prostatic tumor cells (p504s) and 
prostatic basal cells (34βE12,p63,CK 5/6) have proven to beneficious. 
The results showed that, for ambiguous lesions such as atypical small 
acinar proliferation, small foci of prostatic carcinoma not diagnosed ,but 
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suspected to be malignant can be benefited by the use of these markers. 
Immunohistostaining with 34βE12 and p504s has improved diagnostic 
uitility in microscopically difficult cases. It helps to avoid newer and 
subsequent prostatic biopsies ,which are costlier and causing morbidity in 
the patients. The application of these newer antibodies individually is less 
relavant than the combined use of these antibodies. Compared to a new 
series of biopsies, the cost of immunohistochemical  techniques remains 
lower .  
So, the conclusion is that in conjuntion with the clinical scenario 
and morphology, a combination of prostatic epithelial marker AMACR 
and basal cell marker HMWCK is of better value in diagnosing the 
prostate carcinoma cases and other morphologically difficult lesions. 
Hence, the accuracy of diagnosis in prostate cancer is significantly 
increased. However, it should be kept in mind about the limitations of 
both the markers.   
In summary, from several institutions, various type of studies have 
demonstrated that AMACR/ P504S is an important positive epithelial cell 
marker for prostate cancer. A sensitivity ranging from 82% to 95% and a 
specificity ranging from 79% to 100% was achieved, regardless of tumor 
grade; as well as with different criteria for positive stains in benign and 
malignant glands
20,33,36,37,45,59
. 
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 Hence,AMACR has the potential to be a useful  marker which can 
be used seperately for  prostate carcinoma in clinical pathology practice. 
Similarly 34βE12 has a high specificity and sensitivity for identifying 
prostate lesions in biopsies. 
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                                      ANNEXURE 1  
  PROFROMA 
                               
Coimbatore medical college 
Department of pathology 
Coimbatore 
 
 Particulars of the patient:                                                                            
Name:                                                                      Age: 
Ward:                                                                       IP/OP No: 
Address:                                                                   Occupation: 
Presenting complaints: 
            Dysuria 
            Burning micturition 
            Drippling of urine 
Duration of presenting complaint: 
Past history: 
            History of previous surgeries  
            History of chemotherapy/Radiotherapy 
            Family history: 
 Personal history 
             Diet          
General examination 
            Nourishment :                                 Built:                    Consious: 
             Pallor:          Jaundice:           Cyanosis:         Clubbing: 
             PR:             RR:             BP:                     Febrile/afebrile: 
             Lymphadenopathy:                        Edema: 
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Digital Rectal Examination: 
Clinical diagnosis: 
Investigations: 
        Serum PSA level 
           USG Report 
FINAL REPORT 
 Specimen      : Biopsy/TURP 
 HPE Diagnosis  : PC/ PIN/ ASAP / BPH/ BCH 
 Gleason grading  : 
 AMACR   : Positive/ Weak positive/Negative 
 34Beta E12   : Positive/ Weak positive/Negative 
 Final Diagnosis  : PC/ PIN/ ASAP/ BPH/ BCH 
 
  
130 
 
Sno IP No Pt Name Age HPE No Specimen HPE  
Gleason 
grading AMACR 
34Beta 
E12 
Final 
Diagnosis 
1 119110 Saranraj 75 314/11 TURP PC 5+4 negative negative PC 
2 69111 Perumal 63 315/11 Biopsy PC 
 
focal 
positive negative PC 
3 6349 Murugasamy 80 352/11 Biopsy BPH   negative negative BPH 
4 11397 Suyambu 69 486/11 Biopsy PIN   negative negative PIN 
5 11975 Arokiadoss 58 607/11 Biopsy BPH   negative positive BPH 
6 22581 Manickam 72 986/11 Biopsy PC 4+3 negative negative PC 
7 25040 Mani  55 1025/11 Biopsy PC 4+3 positive negative PC 
8 27827 Raju 67 1033/11 TURP PC 4+4 positive negative PC 
9 32900 Ramasamy 85 1229/11 TURP BPH   negative positive BPH 
10 310109 Samraj 75 1293/11 TURP BPH   negative positive BPH 
11 33753 Moosa 58 1296/11 TURP BPH   negative positive BPH 
12 32891 Karuppusamy 80 1312/11 Biopsy PC 5+4 
Focal 
positive negative PC 
13 44229 Karuthachalam 36 1903/11 Biopsy PC 5+4 positive negative PC 
14 4821 Chinnasamy 60 2040/11 Biopsy PIN   
weak 
positive positive PIN 
15 66193 Arumugam 62 2042/11 TURP BPH   negative positive BPH 
16 45496 Vadamalai 65 2209/11 Biopsy PC 4+3 positive negative PC 
17 20431 Muthusamy 55 2235/11 Biopsy PC 4+3 positive negative PC 
18 53840 Subramani 61 2305/11 Biopsy PC 4+3 positive negative PC 
19 52224 Krishnan 75 2363/11 TURP BCH   negative positive BCH 
20 55919 Sampath 50 2441/11 Biopsy PC 4+3 positive negative PC 
21 2072 Arumugam 62 2442/11 Biopsy PC 4+4 positive negative PC 
22 45496 Vadamalai 65 2515/11 Biopsy PC 3+4 positive negative PC 
23 42198 Sugaprama 78 2516/11 Biopsy PC 4+5 positive negative PC 
24 62043 Karuppusamy 70 2646/11 Biopsy ASAP   positive negative ASAP 
25 66418 Karuppusamy 66 2799/11 Biopsy PIN   
weak 
positive dis.positive PIN 
26 70529 Natarajan 74 2972/11 Biopsy BPH   negative positive BPH 
27 2936 Ramalingam 62 137/12 Biopsy BPH   negative positive BPH 
28 17753 Mookannan 80 814/12 Biopsy PIN   
weak 
positive positive PIN 
29 18458 Duraisamy 70 857/12 Biopsy PIN   
weak 
positive positive PIN 
30 18495 Devaraj 64 858/12 Biopsy PC 4+5 positive negative PC 
31 20139 Kasinathan 55 964/12 Biopsy PC 4+4 positive negative PC 
32 22225 Myilsamy 65 965/12 Biopsy PC 3+4 positive negative PC 
33 24813 Moideen 69 1109/12 Biopsy PC 4+5 positive negative PC 
34 41264 Munusamy 68 1986/12 Biopsy PC 4+4 positive negative PC 
35 13452 Kaliappan 59 2313/11 TURP BPH   negative positive BPH 
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KEY TO MASTER CHART 
BPH   –  Benign Prostatic Hyperplasia 
PIN     –  Prostatic Intra Epithelial Neoplasia 
ASAP  –  Atypical Small Acinar Proliferation 
PC   –  Prostatic Carcinoma 
AMACR  –   α-Methyl Acyl CoA Racemase 
HMWCK –  High Molecular Weight Cytokeratin 
HPE   -  Histopathological Examination 
IHC  –  Immunohistochemistry 
H&E   -  Hematoxylin And Eosin Staining  
 
 
 
 
 
 
ABSTRACT 
Prostatic carcinoma accounts for the highest incidence of malignancies in 
men and it is the second most common cause of morbidity. Increased prostate-
specific antigen levels increases needle biopsies, for the exclusion of prostate 
cancer. But, a needle biopsy presents problems, only a small amount of tissue is 
provided for microscopic examination. It is a difficult task to accurately 
diagnose small foci of prostate cancer for pathologists and to distinguish cancer 
from its benign mimickers. Hence, definitive diagnosis with the available 
specimen is essential for the benefit of patients. The diagnosis of prostate 
adenocarcinoma is supported by the absence of basal cells which is highlighted 
by Immunohistochemical markers high-molecular-weight cytokeratin and p63 
but they are negative markers for prostatic carcinoma. Now, a newer marker, 
AMACR (α-Methyl Acyl CoA Racemase) is used in the diagnosis of prostate 
cancers as a positive marker with high sensitivity (76 – 100%) and high 
specificity (75 – 95%). 
TITLE: THE EXPRESSION AND DIAGNOSTIC UTILITY OF AMACR 
AND 34β E 12 IN PROSTATIC LESIONS  
AIM AND OBJECTIVE:  
To study the Expression and Diagnostic utility of Immunohistochemical 
markers AMACR and 34βE12 in various Prostatic lesions. 
 
MATERIALS & METHODS:  
Among the total cases received in the Department of Pathology of our 
hospital during study period, 37 cases were taken into study. Included were 29 
needle biopsies and 8 TURP specimens. 
 The received samples were then fixed in 4% formalin, embedded in 
paraffin and stained with H&E. After eosin and hematoxylin staining all slides 
were reviewed by pathologists and assigned to the following groups - Benign 
prostatic hyperplasia, Basal cell hyperplasia, PIN, malignant and suspicious. 
OBSERVATION & RESULTS: 
 In this study, a total of 37 cases were evaluated. 17 cases prostatic 
carcinoma, 5 cases prostatic intraepithelial neoplasia, 10 benign prostatic 
hyperplasia were detected. The sensitivity of AMACR in detection of prostate 
carcinoma was 90% and specificity was 100%.The sensitivity of 34βE12 
detection of prostate carcinoma was 100% and specificity was 89%. 
CONCLUSION: 
In conjunction with the clinical scenario and morphology, a combination 
of prostatic epithelial marker AMACR and basal cell marker HMWCK is of 
better value in diagnosing the prostate carcinoma cases and other 
morphologically difficult lesions. 
